Literature DB >> 21637635

Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.

Alfons Meindl1, Nina Ditsch, Karin Kast, Kerstin Rhiem, Rita K Schmutzler.   

Abstract

BACKGROUND: Every year, 60,000 women in Germany are found to have breast cancer, and 9000 to have ovarian cancer. Familial clustering of carcinoma is seen in about 20% of cases.
METHODS: We selectively review relevant articles published up to December 2010 that were retrieved by a search in PubMed, and we also discuss findings from the experience of the German Consortium for Hereditary Breast and Ovarian Cancer.
RESULTS: High risk is conferred by the highly penetrant BRCA1 and BRCA2 genes as well as by other genes such as RAD51C. Genes for breast cancer that were originally designated as moderately penetrant display higher penetrance than previously thought in families with a hereditary predisposition. The role these genes play in DNA repair is thought to explain why tumors associated with them are sensitive to platin derivatives and PARP inhibitors. In carriers of BRCA1 and BRCA2, prophylactic bilateral mastectomy and adnexectomy significantly lowers the incidence of breast and ovarian cancer. Moreover, prophylactic adnexectomy also lowers the breast-and-ovarian-cancer-specific mortality, as well as the overall mortality. If a woman bearing a mutation develops cancer in one breast, her risk of developing cancer in the other breast depends on the particular gene that is mutated and on her age at the onset of disease.
CONCLUSION: About half of all monogenically determined carcinomas of the breast and ovary are due to a mutation in one or the other of the highly penetrant BRCA genes (BRCA1 and BRCA2). Women carrying a mutated gene have an 80% to 90% chance of developing breast cancer and a 20% to 50% chance of developing ovarian cancer. Other predisposing genes for breast and ovarian cancer have been identified. Clinicians should develop and implement evidence-based treatments on the basis of these new findings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21637635      PMCID: PMC3106175          DOI: 10.3238/arztebl.2011.0323

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  62 in total

1.  Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.

Authors:  M M A Tilanus-Linthorst; C Alves; C Seynaeve; M B E Menke-Pluymers; A M M Eggermont; C T M Brekelmans
Journal:  Br J Surg       Date:  2006-08       Impact factor: 6.939

2.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.

Authors:  Ellen Warner; Kimberley Hill; Petrina Causer; Donald Plewes; Roberta Jong; Martin Yaffe; William D Foulkes; Parviz Ghadirian; Henry Lynch; Fergus Couch; John Wong; Frances Wright; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

4.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

5.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

6.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

7.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Authors:  Susan M Domchek; Tara M Friebel; Susan L Neuhausen; Theresa Wagner; Gareth Evans; Claudine Isaacs; Judy E Garber; Mary B Daly; Rosalind Eeles; Ellen Matloff; Gail E Tomlinson; Laura Van't Veer; Henry T Lynch; Olufunmilayo I Olopade; Barbara L Weber; Timothy R Rebbeck
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

8.  Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

Authors:  Susan J Ramus; Christiana Kartsonaki; Simon A Gayther; Paul D P Pharoah; Olga M Sinilnikova; Jonathan Beesley; Xiaoqing Chen; Lesley McGuffog; Sue Healey; Fergus J Couch; Xianshu Wang; Zachary Fredericksen; Paolo Peterlongo; Siranoush Manoukian; Bernard Peissel; Daniela Zaffaroni; Gaia Roversi; Monica Barile; Alessandra Viel; Anna Allavena; Laura Ottini; Laura Papi; Viviana Gismondi; Fabio Capra; Paolo Radice; Mark H Greene; Phuong L Mai; Irene L Andrulis; Gord Glendon; Hilmi Ozcelik; Mads Thomassen; Anne-Marie Gerdes; Torben A Kruse; Dorthe Cruger; Uffe Birk Jensen; Maria Adelaide Caligo; Håkan Olsson; Ulf Kristoffersson; Annika Lindblom; Brita Arver; Per Karlsson; Marie Stenmark Askmalm; Ake Borg; Susan L Neuhausen; Yuan Chun Ding; Katherine L Nathanson; Susan M Domchek; Anna Jakubowska; Jan Lubiński; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Bohdan Górski; Cezary Cybulski; Tadeusz Dębniak; Ana Osorio; Mercedes Durán; Maria-Isabel Tejada; Javier Benítez; Ute Hamann; Matti A Rookus; Senno Verhoef; Madeleine A Tilanus-Linthorst; Maaike P Vreeswijk; Danielle Bodmer; Margreet G E M Ausems; Theo A van Os; Christi J Asperen; Marinus J Blok; Hanne E J Meijers-Heijboer; Susan Peock; Margaret Cook; Clare Oliver; Debra Frost; Alison M Dunning; D Gareth Evans; Ros Eeles; Gabriella Pichert; Trevor Cole; Shirley Hodgson; Carole Brewer; Patrick J Morrison; Mary Porteous; M John Kennedy; Mark T Rogers; Lucy E Side; Alan Donaldson; Helen Gregory; Andrew Godwin; Dominique Stoppa-Lyonnet; Virginie Moncoutier; Laurent Castera; Sylvie Mazoyer; Laure Barjhoux; Valérie Bonadona; Dominique Leroux; Laurence Faivre; Rosette Lidereau; Catherine Nogues; Yves-Jean Bignon; Fabienne Prieur; Marie-Agnès Collonge-Rame; Laurence Venat-Bouvet; Sandra Fert-Ferrer; Alex Miron; Saundra S Buys; John L Hopper; Mary B Daly; Esther M John; Mary Beth Terry; David Goldgar; Thomas v O Hansen; Lars Jønson; Bent Ejlertsen; Bjarni A Agnarsson; Kenneth Offit; Tomas Kirchhoff; Joseph Vijai; Ana V C Dutra-Clarke; Jennifer A Przybylo; Marco Montagna; Cinzia Casella; Evgeny N Imyanitov; Ramunas Janavicius; Ignacio Blanco; Conxi Lázaro; Kirsten B Moysich; Beth Y Karlan; Jenny Gross; Mary S Beattie; Rita Schmutzler; Barbara Wappenschmidt; Alfons Meindl; Ina Ruehl; Britta Fiebig; Christian Sutter; Norbert Arnold; Helmut Deissler; Raymonda Varon-Mateeva; Karin Kast; Dieter Niederacher; Dorothea Gadzicki; Trinidad Caldes; Miguel de la Hoya; Heli Nevanlinna; Kristiina Aittomäki; Jacques Simard; Penny Soucy; Amanda B Spurdle; Helene Holland; Georgia Chenevix-Trench; Douglas F Easton; Antonis C Antoniou
Journal:  J Natl Cancer Inst       Date:  2010-12-17       Impact factor: 13.506

9.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  Genome-wide association study identifies novel breast cancer susceptibility loci.

Authors:  Douglas F Easton; Karen A Pooley; Alison M Dunning; Paul D P Pharoah; Deborah Thompson; Dennis G Ballinger; Jeffery P Struewing; Jonathan Morrison; Helen Field; Robert Luben; Nicholas Wareham; Shahana Ahmed; Catherine S Healey; Richard Bowman; Kerstin B Meyer; Christopher A Haiman; Laurence K Kolonel; Brian E Henderson; Loic Le Marchand; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Fabrice Odefrey; Chen-Yang Shen; Pei-Ei Wu; Hui-Chun Wang; Diana Eccles; D Gareth Evans; Julian Peto; Olivia Fletcher; Nichola Johnson; Sheila Seal; Michael R Stratton; Nazneen Rahman; Georgia Chenevix-Trench; Stig E Bojesen; Børge G Nordestgaard; Christen K Axelsson; Montserrat Garcia-Closas; Louise Brinton; Stephen Chanock; Jolanta Lissowska; Beata Peplonska; Heli Nevanlinna; Rainer Fagerholm; Hannaleena Eerola; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; David J Hunter; Susan E Hankinson; David G Cox; Per Hall; Sara Wedren; Jianjun Liu; Yen-Ling Low; Natalia Bogdanova; Peter Schürmann; Thilo Dörk; Rob A E M Tollenaar; Catharina E Jacobi; Peter Devilee; Jan G M Klijn; Alice J Sigurdson; Michele M Doody; Bruce H Alexander; Jinghui Zhang; Angela Cox; Ian W Brock; Gordon MacPherson; Malcolm W R Reed; Fergus J Couch; Ellen L Goode; Janet E Olson; Hanne Meijers-Heijboer; Ans van den Ouweland; André Uitterlinden; Fernando Rivadeneira; Roger L Milne; Gloria Ribas; Anna Gonzalez-Neira; Javier Benitez; John L Hopper; Margaret McCredie; Melissa Southey; Graham G Giles; Chris Schroen; Christina Justenhoven; Hiltrud Brauch; Ute Hamann; Yon-Dschun Ko; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Arto Mannermaa; Veli-Matti Kosma; Vesa Kataja; Jaana Hartikainen; Nicholas E Day; David R Cox; Bruce A J Ponder
Journal:  Nature       Date:  2007-06-28       Impact factor: 49.962

View more
  43 in total

1.  Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India.

Authors:  Ashraf U Mannan; Jaya Singh; Ravikiran Lakshmikeshava; Nishita Thota; Suhasini Singh; T S Sowmya; Avshesh Mishra; Aditi Sinha; Shivani Deshwal; Megha R Soni; Anbukayalvizhi Chandrasekar; Bhargavi Ramesh; Bharat Ramamurthy; Shila Padhi; Payal Manek; Ravi Ramalingam; Suman Kapoor; Mithua Ghosh; Satish Sankaran; Arunabha Ghosh; Vamsi Veeramachaneni; Preveen Ramamoorthy; Ramesh Hariharan; Kalyanasundaram Subramanian
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

2.  Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up.

Authors:  Günther Schellong; Marianne Riepenhausen; Karoline Ehlert; Jürgen Brämswig; Wolfgang Dörffel; Rita K Schmutzler; Kerstin Rhiem; Ulrich Bick
Journal:  Dtsch Arztebl Int       Date:  2014-01-06       Impact factor: 5.594

Review 3.  Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.

Authors:  Kerstin Rhiem; Rita Schmutzler
Journal:  Breast Care (Basel)       Date:  2014-12       Impact factor: 2.860

4.  After initial treatment for primary breast cancer: information needs, health literacy, and the role of health care workers.

Authors:  Anna Schmidt; Nicole Ernstmann; Simone Wesselmann; Holger Pfaff; Markus Wirtz; Christoph Kowalski
Journal:  Support Care Cancer       Date:  2015-06-25       Impact factor: 3.603

Review 5.  Intensified surveillance for early detection of breast cancer in high-risk patients.

Authors:  Ulrich Bick
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

6.  Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.

Authors:  Christine M Kivlin; Kelsey L Watson; Ghadah A Al Sannaa; Roman Belousov; Davis R Ingram; Kai-Lieh Huang; Caitlin D May; Svetlana Bolshakov; Sharon M Landers; Azad Abul Kalam; John M Slopis; Ian E McCutcheon; Raphael E Pollock; Dina Lev; Alexander J Lazar; Keila E Torres
Journal:  Cancer Biol Ther       Date:  2015-12-09       Impact factor: 4.742

Review 7.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

Authors:  Lindsey E Romick-Rosendale; Vivian W Y Lui; Jennifer R Grandis; Susanne I Wells
Journal:  Mutat Res       Date:  2013-01-17       Impact factor: 2.433

8.  Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.

Authors:  Marion Myklebust; Eva Gjengedal; Nina Strømsvik
Journal:  J Genet Couns       Date:  2016-04-19       Impact factor: 2.537

9.  Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.

Authors:  K Rhiem; K Pfeifer; R K Schmutzler; M Kiechle
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-09       Impact factor: 2.915

10.  No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.

Authors:  Judith Penkert; Brigitte Schlegelberger; Doris Steinemann; Dorothea Gadzicki
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.